Trevi Therapeutics, Inc.

TRVI · Nasdaq · United States

Share price · TRVI

$13.51-5.33 (-28.29%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.1M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TRVI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Nov 2026-8.1%

    Nothing announced by TRVI that day or the session before.

  2. 6 Nov 2026+11.9%

    Nothing announced by TRVI that day or the session before.

  3. 27 Oct 2026+6.7%

    Nothing announced by TRVI that day or the session before.

  4. 20 Oct 2026+7.8%

    Nothing announced by TRVI that day or the session before.

  5. 20 Jul 2026-12.1%

    Nothing announced by TRVI that day or the session before.

  6. 17 Jul 2026+9.9%

    Nothing announced by TRVI that day or the session before.

  7. 14 Jul 2026+8.4%

    Nothing announced by TRVI that day or the session before.

  8. 13 Jul 2026-7.4%

    Nothing announced by TRVI that day or the session before.

  9. 7 Jul 2026+8.6%

    Nothing announced by TRVI that day or the session before.

  10. 16 Jun 2026+5.0%

    Nothing announced by TRVI that day or the session before.

Share of unusual movement by asset

For each asset, the share of TRVI's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Nalbuphine ER (Haduvio)
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—10%
Sessions with no dated event—87%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Nalbuphine ER(Haduvio)
Phase 3
Kappa-opioid receptor (agonist); mu-opioid receptor (antagonist)Small molecule
Prurigo NodularisIdiopathic Pulmonary Fibrosis
Chronic Cough in Idiopathic Pulmonary Fibrosis

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
August 2027 (1)
Nalbuphine ER · HaduvioPhase 3Idiopathic Pulmonary Fibrosis
Est. primary completion 2027-08 · NCT07868419 · CT.gov ↗
What to watch
September 2027 (1)
Nalbuphine ER · HaduvioPhase 2Refractory Chronic Cough
Est. primary completion 2027-09 · NCT07671924 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Nalbuphine ER · HaduvioPhase 3Idiopathic Pulmonary Fibrosis
Est. primary completion 2028-06 · NCT07671911 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 June 2025Topline resultNalbuphine ERPhase 2b CORAL of Haduvio (nalbuphine ER) in IPF chronic cough met its primary endpoint
Trevi Therapeutics, Inc. · Source ↗
10 March 2025Topline resultNalbuphine ERPositive topline results from Phase 2a RIVER trial of Haduvio in RCC

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$19M$28M+ $272M short-term inv.$21M-$20M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$15M$54M+ $265M short-term inv.$18M-$17M operating cash flowreport ↗
2026-Q1—$9.9M$19M+ $152M short-term inv.$13M-$17M operating cash flowreport ↗
2025-Q3—$10M$57M+ $138M short-term inv.$12M-$11M operating cash flowreport ↗
2025-Q2—$9.4M$117M+ $87M short-term inv.$12M-$10M operating cash flowreport ↗
2025-Q1—$7.8M$19M+ $84M short-term inv.$10M-$13M operating cash flowreport ↗
2024-Q3—$11M$16M+ $49M short-term inv.$13M-$9.6M operating cash flowreport ↗
2024-Q2—$10M$13M+ $57M short-term inv.$12M-$8.7M operating cash flowreport ↗
2024-Q1—$8.8M$14M+ $59M short-term inv.$11M-$10M operating cash flowreport ↗
2023-Q3—$6.3M$26M+ $63M short-term inv.$7.7M-$7.3M operating cash flowreport ↗
2023-Q2—$5.8M$14M+ $80M short-term inv.$7.2M-$9.9M operating cash flowreport ↗
2023-Q1—$5.0M$12M+ $100M short-term inv.$6.4M-$8.2M operating cash flowreport ↗
2022-Q3—$5.8M$67M+ $59M short-term inv.$8.3M-$8.6M operating cash flowreport ↗
2022-Q2—$5.1M$25M+ $53M short-term inv.$8.1M-$6.2M operating cash flowreport ↗
2022-Q1—$4.6M$29M$7.3M-$7.1M operating cash flowreport ↗
2021-Q3—$4.7M$29M$7.3M-$7.2M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$33M$19M+ $169M short-term inv.$11M-$42M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$39M$34M+ $74M short-term inv.$12M-$38M operating cash flowreport ↗
2023-FY—$24M$32M+ $51M short-term inv.$7.3M-$32M operating cash flowreport ↗
2022-FY—$20M$13M+ $108M short-term inv.$7.3M-$28M operating cash flowreport ↗
2021-FY—$23M$37M$8.5M-$29M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($596K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-15Heffernan Michael Thomas · directorOption exercise18,421$3.04$56KForm 4
2026-09-15Heffernan Michael Thomas · directorOpen-market sale18,321$15.09$276KForm 4
2026-09-15Heffernan Michael Thomas · directorOpen-market sale100$15.88$2KForm 4
2026-09-15Heffernan Michael Thomas · directorOption exercise21,052$3.33$70KForm 4
2026-09-15Heffernan Michael Thomas · directorOpen-market sale20,952$15.09$316KForm 4
2026-09-15Heffernan Michael Thomas · directorOpen-market sale100$15.88$2KForm 4
2026-09-15Heffernan Michael Thomas · directorOption exercise (derivative)18,421——Form 4
2026-09-15Heffernan Michael Thomas · directorOption exercise (derivative)21,052——Form 4